Sequoia Financial Advisors LLC Purchases 2,064 Shares of Revvity, Inc. (NYSE:RVTY)

Sequoia Financial Advisors LLC grew its position in shares of Revvity, Inc. (NYSE:RVTY) by 8.6% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 25,929 shares of the company’s stock after purchasing an additional 2,064 shares during the period. Sequoia Financial Advisors LLC’s holdings in Revvity were worth $2,894,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in RVTY. Empirical Finance LLC lifted its stake in shares of Revvity by 2.0% in the 3rd quarter. Empirical Finance LLC now owns 4,237 shares of the company’s stock valued at $541,000 after acquiring an additional 85 shares during the last quarter. Wealth Enhancement Advisory Services LLC lifted its stake in shares of Revvity by 2.4% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 4,214 shares of the company’s stock valued at $470,000 after acquiring an additional 100 shares during the last quarter. HB Wealth Management LLC lifted its stake in shares of Revvity by 4.6% in the 4th quarter. HB Wealth Management LLC now owns 2,380 shares of the company’s stock valued at $266,000 after acquiring an additional 104 shares during the last quarter. Westside Investment Management Inc. lifted its stake in shares of Revvity by 0.8% in the 4th quarter. Westside Investment Management Inc. now owns 14,363 shares of the company’s stock valued at $1,603,000 after acquiring an additional 108 shares during the last quarter. Finally, Coldstream Capital Management Inc. lifted its stake in shares of Revvity by 5.1% in the 3rd quarter. Coldstream Capital Management Inc. now owns 2,247 shares of the company’s stock valued at $286,000 after acquiring an additional 110 shares during the last quarter. Institutional investors own 86.65% of the company’s stock.

Revvity Stock Down 1.1 %

RVTY stock opened at $110.29 on Friday. Revvity, Inc. has a fifty-two week low of $97.32 and a fifty-two week high of $129.50. The business’s 50 day moving average price is $117.04 and its two-hundred day moving average price is $118.04. The company has a debt-to-equity ratio of 0.41, a quick ratio of 3.03 and a current ratio of 3.60. The company has a market capitalization of $13.25 billion, a price-to-earnings ratio of 49.91, a price-to-earnings-growth ratio of 3.82 and a beta of 1.06.

Revvity (NYSE:RVTY) last posted its quarterly earnings results on Friday, January 31st. The company reported $1.42 earnings per share for the quarter, topping the consensus estimate of $1.37 by $0.05. Revvity had a return on equity of 7.68% and a net margin of 9.81%. During the same period in the prior year, the company posted $1.25 EPS. As a group, analysts forecast that Revvity, Inc. will post 4.94 earnings per share for the current fiscal year.

Revvity Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, May 9th. Investors of record on Friday, April 18th will be paid a $0.07 dividend. The ex-dividend date of this dividend is Thursday, April 17th. This represents a $0.28 annualized dividend and a dividend yield of 0.25%. Revvity’s payout ratio is currently 12.67%.

Insider Buying and Selling

In other Revvity news, insider Joel S. Goldberg sold 15,170 shares of the stock in a transaction on Thursday, January 30th. The stock was sold at an average price of $126.73, for a total transaction of $1,922,494.10. Following the sale, the insider now directly owns 33,400 shares in the company, valued at approximately $4,232,782. This trade represents a 31.23 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Tajinder S. Vohra sold 5,492 shares of the stock in a transaction on Tuesday, January 7th. The shares were sold at an average price of $116.81, for a total value of $641,520.52. Following the sale, the insider now owns 19,652 shares in the company, valued at approximately $2,295,550.12. This represents a 21.84 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.60% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on the company. Barclays boosted their target price on Revvity from $135.00 to $140.00 and gave the company an “overweight” rating in a research note on Monday, February 3rd. Sanford C. Bernstein lowered Revvity from an “outperform” rating to a “market perform” rating and set a $130.00 target price for the company. in a research note on Friday, January 10th. Raymond James reissued an “outperform” rating and issued a $145.00 target price (up previously from $140.00) on shares of Revvity in a research note on Monday, February 3rd. KeyCorp upped their price target on Revvity from $132.00 to $145.00 and gave the company an “overweight” rating in a research report on Monday, February 3rd. Finally, Bank of America raised Revvity from a “neutral” rating to a “buy” rating and set a $138.00 price target for the company in a research report on Friday, December 13th. Four equities research analysts have rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $136.25.

Revvity Company Profile

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.